Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • amyloidosis

    - PMLiVE

    Alnylam’s Amvuttra approved by MHRA to treat rare heart disease ATTR-CM

    The drug has been authorised to treat both wild-type and hereditary forms of the disease

    - PMLiVE

    GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

    The decision means that eligible patients in England will be the first in the world to access the combination

    - PMLiVE

    Alnylam’s Amvuttra granted EC approval to treat rare heart disease ATTR-CM

    The RNAi therapeutic has been authorised to treat both wild type and hereditary forms of the disease

    - PMLiVE

    Alnylam shares phase 3 results for Amvuttra in rare heart disease ATTR-CM

    Transthyretin amyloid cardiomyopathy is estimated to affect over 300,000 people worldwide

    - PMLiVE

    Alnylam’s RNAi therapeutic vutrisiran recommended by CHMP for rare heart disease

    The committee has recommended the drug for both wild type and hereditary ATTR-CM

    - PMLiVE

    Alnylam’s Amvuttra granted FDA approval for rare heart disease ATTR-CM

    Approximately 150,000 people in the US are affected by transthyretin amyloid cardiomyopathy

    - PMLiVE

    NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

    Around 1,000 patients could benefit from the relugolix combination therapy every year

    - PMLiVE

    Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

    Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

    - PMLiVE

    AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi

    More than 49,000 people are diagnosed with lung cancer in the UK each year

    - PMLiVE

    NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

    Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

    - PMLiVE

    NICE recommends Immunocore’s Kimmtrak as first drug for aggressive eye cancer

    More than 100 patients are expected to be eligible for the treatment every year

    - PMLiVE

    NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder

    Systemic mastocytosis affects approximately one in every 10,000 people in the UK

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links